← Back to headlines
Kailera Stock Falls Following Late-Stage Trial Data for GLP-1 Candidate
Kailera's shares experienced a decline after the release of late-stage trial data for its oral GLP-1 candidate. The specific details of the trial data and the extent of the stock drop were not immediately clear.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally
1h ago
Pentagon Temporarily Rescinds Mandatory Testosterone Screening Guidance for Troops
1h ago
Experts Warn Obsessive Sleep Tracking May Disrupt Rest Quality
3h ago
UNICEF Reports 20 Million Children Face Annual Online Sexual Abuse
3h ago